Miramoon Pharma
First-in-class small molecules for neurodegenerative and rare diseases
Website: https://www.miramoonpharma.com/
Cover Block
PUBLIC
| Attribute | Detail |
|---|---|
| Name | Miramoon Pharma |
| Tagline | First-in-class small molecules for neurodegenerative and rare diseases |
| Headquarters | San Sebastián, Spain |
| Founded | 2019 |
| Stage | Seed |
| Business Model | Other (Strategic licensing-out and co-development) [AseBio] |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout (University of the Basque Country, Biogipuzkoa Health Research Institute) [El Referente] |
| Funding Label | Undisclosed |
Links
PUBLIC
- Website: https://www.miramoonpharma.com/
- LinkedIn: https://es.linkedin.com/company/miramoon.pharma
Executive Summary
PUBLIC
Miramoon Pharma is a Spanish biotech spinout pursuing a novel, platform-based pharmacological approach to neurodegenerative and rare diseases, with its lead asset having already secured valuable regulatory designations. The company's scientific premise centers on small molecules that modulate FKBP12 to stabilize calcium channels and inhibit oxidative stress, targeting a fundamental cellular dysfunction common across multiple conditions [Miramoon Pharma]. Founded in 2019 as a spin-off from the University of the Basque Country and the Biogipuzkoa Health Research Institute, the company exemplifies the deep academic roots common in European life sciences ventures [El Referente]. Its lead program, MP-004, is in preclinical development for retinitis pigmentosa and has obtained Orphan Drug Designation from both the FDA and EMA, a milestone that provides regulatory and potential commercial benefits [AseBio, Nov 2025].
Operational leadership appears to rest with CEO Amalia Capilla, whose background includes over two decades in molecular biology and biotech, though the founding scientific team's public profile remains limited [economia3.com]. Capitalization is opaque; while regional venture firms BStartup10 and Pinama Capital are listed as investors, no round sizes, dates, or a clear post-money valuation have been disclosed, leaving the company's financial runway an open question [Capital-Riesgo.es]. The immediate catalyst for investor attention is the planned transition to clinical trials, with the company targeting a 2026 start for MP-004's first-in-human studies, a step that will require significant capital and serve as the first major de-risking event for the platform [SPRI].
Data Accuracy: YELLOW -- Core product and regulatory milestones are documented; funding details and precise team roles lack full public corroboration.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Seed |
| Business Model | Other |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout |
| Funding | Undisclosed |
Company Overview
PUBLIC
Miramoon Pharma was founded in 2019 as a spin-off from the University of the Basque Country and the Biogipuzkoa Health Research Institute, anchoring its research in the regional academic ecosystem of San Sebastián, Spain [El Referente]. The company's founding premise was to translate basic research on calcium dysregulation in neurodegenerative diseases into a pipeline of first-in-class small molecules [Miramoon Pharma website].
Leadership is provided by Amalia Capilla, identified as the company's Chief Executive Officer [economia3.com]. Capilla is reported to have more than twenty years of experience in molecular biology and biotech companies in both Spain and the United States [BStartup Banco Sabadell]. The founder and Chief Medical Officer is Dr. Adolfo López de Munain [AseBio]. The company operates as a consortium, collaborating with institutions including the University of Barcelona, the University of the Basque Country, and the Margarita Salas Biological Research Centre [Biotech Spain].
Key corporate milestones follow a preclinical biotech trajectory. The lead asset, MP-004, secured Orphan Drug Designation from both the U.S. Food and Drug Administration and the European Medicines Agency for retinitis pigmentosa, a significant regulatory validation [AseBio, Nov 2025]. Preclinical efficacy data for MP-004 has been published in peer-reviewed journals such as Investigative Ophthalmology & Visual Science [IOVS | ARVO Journals]. The company has stated plans to initiate clinical trials in 2026 [SPRI].
Data Accuracy: YELLOW -- Key leadership and founding details are confirmed by multiple regional sources, but the specific timeline of the seed investment and corporate structure lacks independent corroboration.
Product and Technology
MIXED The company’s value proposition rests on a platform of novel small molecules designed to correct a specific cellular dysfunction common across several severe diseases. Miramoon Pharma’s lead asset, MP-004, is a preclinical compound targeting retinitis pigmentosa, an inherited retinal disease with no approved global therapy [Miramoon Pharma website]. The molecule is described as a novel FKBP12 ligand that modulates the activity of the ryanodine receptor RyR2, a channel involved in calcium release within cells [bioRxiv, 2024]. By stabilizing this channel and inhibiting reactive oxygen species, the compound aims to restore calcium homeostasis and prevent the photoreceptor cell death that causes blindness [AseBio, Nov 2025]. This mechanism is positioned as potentially applicable to a broad spectrum of retinitis pigmentosa cases, regardless of the underlying genetic mutation [Biotech Spain].
Beyond the lead program, the company has publicly disclosed a pipeline of four additional programs in the lead nomination stage. These target Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), ALS, and Alzheimer’s disease [Miramoon Pharma website]. The unifying thread across the portfolio appears to be the targeting of calcium dysregulation, a pathological hallmark in many neurodegenerative and neuromuscular conditions. For MP-004, the intended route of administration is topical eye drops, which has shown efficacy in improving retinal function and structure in a mouse model of the disease, according to a peer-reviewed publication [IOVS | ARVO Journals]. A subsequent preprint further assesses the compound’s pharmacological and safety profile following topical administration [bioRxiv, 2025].
The most significant public validation for MP-004 is its regulatory status. The compound has secured Orphan Drug Designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of retinitis pigmentosa [AseBio, Nov 2025]. This designation provides certain development incentives and market exclusivity benefits. The company has stated it is completing pre-IND (Investigational New Drug) studies and plans to initiate a clinical trial in 2026 [SPRI]. The business model, as described on the company website, involves pursuing strategic licensing-out or co-development agreements with larger pharmaceutical companies or venture capital firms once pipeline assets reach an optimal maturity level [Miramoon Pharma website].
Data Accuracy: YELLOW -- Pipeline and mechanism details are confirmed by company website and peer-reviewed/preprint sources. Orphan Drug Designation is reported by a single industry association (AseBio). Clinical trial timing is cited by a regional development agency.
Market Research
PUBLIC
The market for treatments addressing rare, genetically complex neurodegenerative diseases has become a focal point for biotech investment, driven by high unmet need and the potential for premium pricing under orphan drug incentives.
Retinitis pigmentosa (RP), the initial target for Miramoon's lead asset, represents a clear, defined addressable population. The condition affects over 2 million people worldwide, according to a November 2025 report from AseBio, the Spanish Bioindustry Association [AseBio, Nov 2025]. This global prevalence underpins the company's regulatory strategy, as securing Orphan Drug Designation from both the FDA and EMA for MP-004 provides a pathway to market exclusivity and development support despite the relatively small patient population [AseBio, Nov 2025]. The broader neurodegenerative disease pipeline,targeting Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), ALS, and Alzheimer's,significantly expands the potential addressable market. For context, the global market for Alzheimer's disease therapeutics alone was valued at approximately $4.9 billion in 2023 and is projected to grow, according to a Grand View Research report from that year (analogous market, source) [Grand View Research, 2023].
Demand is anchored in the absence of effective disease-modifying treatments for many of these conditions. The company's scientific premise, targeting calcium dysregulation via FKBP12 modulation, is positioned to address a pathological mechanism common across multiple diseases, potentially creating a platform with applications beyond a single indication [Miramoon Pharma website]. This mechanistic breadth is a key tailwind, as successful validation in one disease could de-risk development in others. Furthermore, the regulatory environment in both the US and EU continues to favor orphan drug development, with expedited review pathways and financial incentives that lower the capital intensity barrier for small biotechs.
Key adjacent and substitute markets include gene therapies and antisense oligonucleotides, which are also pursuing rare genetic disorders. These modalities often target specific genetic mutations, whereas Miramoon's small-molecule approach aims for a broader spectrum of RP cases, potentially applicable to cases caused by mutations in more than 350 genes [Biotech Spain]. This positions the technology as a potential pan-RP treatment, a significant differentiator in a field where many therapies are mutation-specific. Macro forces, including aging populations in developed economies and increased genetic screening, are likely to sustain long-term demand for neurodegenerative disease interventions, though near-term success hinges entirely on clinical validation.
Retinitis Pigmentosa (Global Prevalence) | 2 | million patients
The cited patient population for retinitis pigmentosa provides a concrete, if high-level, sizing anchor. The more consequential market sizing exercise lies in the potential value of the platform across its pipeline indications, where analogous markets for conditions like Alzheimer's run into the billions.
Data Accuracy: YELLOW -- Market size for retinitis pigmentosa is cited by an industry association. Analogous market data for broader indications is drawn from a separate, dated third-party report.
Competitive Landscape
MIXED Miramoon Pharma's competitive position rests on a narrow, mechanism-specific approach to calcium dysregulation, a path that has attracted both large pharmaceutical incumbents and specialized biotech challengers.
Retinitis Pigmentosa (RP) | 2 | million patients
The chart illustrates the total addressable patient population for Miramoon's lead indication, a figure that underpins the commercial interest in a space with limited treatment options [AseBio, Nov 2025].
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Miramoon Pharma | FKBP12-modulating small molecules for calcium dysregulation in neurodegenerative/rare diseases. | Preclinical; Seed round (undisclosed) led by BStartup10. | Orphan Drug Designation for lead asset MP-004 (RP); broad mechanism potentially applicable across >350 genetic mutations. | [Miramoon Pharma website]; [AseBio, Nov 2025]; [Capital-Riesgo.es] |
| Nacuity Pharmaceuticals | Developing small molecule antioxidants (NACA) for ocular diseases including retinitis pigmentosa. | Clinical stage (Phase 2/3). | Direct antioxidant approach targeting oxidative stress, a downstream consequence of cellular dysfunction. | [PUBLIC] |
| Neurotech Pharmaceuticals | NT-501 CNTF-secreting implant for retinitis pigmentosa and geographic atrophy. | Approved (RP) and clinical stage. | Sustained-release implantable device delivering a neurotrophic factor, a different therapeutic modality. | [PUBLIC] |
| AbbVie | Global pharmaceutical with legacy interest in ophthalmology via acquisitions (Allergan). | Commercial; multi-billion dollar R&D. | Deep commercial infrastructure and financial resources for late-stage development and global commercialization. | [PUBLIC] |
| SparingVision | Gene-agnostic gene therapy (SPVN06) for retinitis pigmentosa. | Clinical stage (Phase I/II). | AAV-based gene therapy delivering a neurotrophic factor, aiming for a one-time treatment. | [PUBLIC] |
The competitive map for retinitis pigmentosa and related neurodegenerative conditions is segmented by therapeutic modality rather than just by target indication. In the small molecule segment, Miramoon faces direct, albeit mechanistically distinct, competition from firms like Nacuity Pharmaceuticals, which is already in late-stage clinical trials with an antioxidant. The more significant long-term threats come from adjacent modalities: gene therapies (SparingVision) and implantable devices (Neurotech Pharmaceuticals) that promise durable, potentially curative effects, altering the standard of care. Large pharma, represented here by AbbVie, operates as a consolidator and commercial partner rather than a direct early-stage competitor, but its presence defines the ultimate exit landscape and the bar for compelling data.
Miramoon's defensible edge today is regulatory and mechanistic. Securing Orphan Drug Designation from both the FDA and EMA for MP-004 provides seven years of market exclusivity in the US and ten years in Europe upon approval, a significant commercial moat [AseBio, Nov 2025]. Scientifically, the company's focus on stabilizing ryanodine receptor (RyR) channels via FKBP12 modulation addresses upstream calcium dysregulation, a purported root cause across many genetic mutations. This could offer a broader therapeutic profile than mutation-specific gene therapies. However, this edge is perishable and hinges entirely on translational success. The durability of the advantage will be tested in the clinic; negative Phase I safety or efficacy data would erode it immediately, while a competitor's positive Phase III readout in the same indication could redefine the market before Miramoon arrives.
The company's most acute exposure is its preclinical stage versus clinical-stage peers. Nacuity is in Phase 2/3 trials, and SparingVision has begun clinical testing. This gap represents a 3-5 year development and data deficit that impacts partnership use and valuation. Furthermore, Miramoon's platform approach, while theoretically broad, requires significant capital to prosecute multiple rare disease programs (DMD, DM1, ALS, Alzheimer's) concurrently. This exposes the company to resource dilution in a capital-intensive sector where focused, single-asset competitors can advance more rapidly. The company also lacks visible international visibility or a named, serial-founder leadership team with a track record of biotech exits, which may hinder its ability to attract top-tier global venture capital beyond its regional Spanish investors.
The most plausible 18-month scenario involves increased stratification between modality winners. If SparingVision's gene therapy reports positive interim clinical data, it would likely consolidate investor enthusiasm and partnership interest around gene-agnostic approaches, potentially marginalizing small molecule entrants. In that scenario, SparingVision would be the winner. Conversely, if gene therapy safety concerns persist or efficacy is limited, and a small molecule like Nacuity's reports successful Phase 3 results, the landscape would pivot toward oral/topical treatments. Miramoon would be a loser in that specific short-term scenario if it remains in preclinical studies while a competitor sets a new efficacy benchmark, making its future fundraising and partnership discussions more challenging. Miramoon's path to relevance in this period is narrowly defined: translating its Orphan Drug Designation into a clean IND filing and initiating its first clinical trial on schedule in 2026 [SPRI].
Data Accuracy: YELLOW -- Competitor profiles are publicly available, but Miramoon's specific competitive advantages are based on company claims and regulatory status from a single industry association report.
Opportunity
PUBLIC The prize for Miramoon Pharma is a portfolio of first-in-class therapies for a set of severe, underserved diseases, each with a clear regulatory and commercial path defined by Orphan Drug Designation.
The headline opportunity is to become a specialized biotech with multiple approved drugs for rare neurodegenerative and retinal diseases, built on a platform that validates calcium dysregulation as a targetable mechanism. This outcome is reachable, not merely aspirational, because the company has already secured the critical regulatory recognition that de-risks clinical development and commercial exclusivity for its lead asset. MP-004's Orphan Drug Designation from both the FDA and EMA for retinitis pigmentosa provides seven years of market exclusivity in the US and ten years in the EU upon approval, a tangible milestone that precedes clinical data [AseBio, Nov 2025]. The company's stated plan to initiate clinical trials in 2026 provides a near-term catalyst to begin translating this regulatory advantage into clinical validation [SPRI].
Multiple growth scenarios exist beyond the lead program. The pipeline's breadth across Duchenne muscular dystrophy, myotonic dystrophy, ALS, and Alzheimer's suggests a deliberate strategy to use the core FKBP12-modulating platform across related indications with high unmet need.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Lead Asset Approval | MP-004 becomes the first topical therapy approved for retinitis pigmentosa, capturing a global patient population with no effective treatment. | Successful Phase I/II trial results demonstrating safety and efficacy in humans. | Orphan Designation is in hand, preclinical data shows improved retinal function in models [IOVS |
| Platform Validation & Partnership | Positive data for MP-004 validates the calcium modulation platform, triggering a major licensing deal for one of the other pipeline programs (e.g., for DMD or ALS). | Announcement of a co-development or licensing agreement with a mid-to-large pharma partner. | The company's stated business model is "strategic licensing-out and co-development agreements" once molecules reach maturity [Miramoon Pharma website]. A lead asset in the clinic would make the platform tangible for partners. |
| Portfolio Expansion | The company advances a second program into clinical trials, demonstrating it can serially develop candidates and creating a pipeline value beyond a single asset. | IND submission for a second program (e.g., for DM1 or Alzheimer's). | Four additional programs are reported in lead nomination stages, indicating active preclinical work [Miramoon Pharma website]. Success with the first candidate would attract capital to fund the next. |
What compounding looks like is a scientific and commercial flywheel. Each clinical milestone for MP-004 generates data that reinforces the underlying platform's credibility. This, in turn, lowers the perceived risk for investors and potential partners regarding the other pipeline programs, making subsequent financing or deal terms more favorable. Early validation could also attract specialized talent from larger biopharma, accelerating development cycles. The consortium structure with several Spanish academic institutions provides a built-in network for ongoing research and candidate discovery [Biotech Spain], acting as an early-stage R&D flywheel.
The size of the win can be framed by looking at comparable orphan drug developers. For a scenario where MP-004 gains approval for retinitis pigmentosa, a relevant precedent is the valuation of publicly traded micro-cap biotechs with a single approved orphan drug, which often trade in the hundreds of millions of dollars range. A more direct, though earlier-stage, comparison might be to private biotechs that have secured significant venture funding after achieving Orphan Designation for a retinal disease asset. While no precise acquisition multiple is cited for Miramoon, the global addressable market for its lead indication provides scale: retinitis pigmentosa affects over 2 million people worldwide [AseBio, Nov 2025]. In a successful approval scenario, even capturing a modest percentage of this global patient population with a therapy priced in line with other orphan drugs could support a valuation well into the hundreds of millions. This is a scenario-specific outcome, not a forecast.
Data Accuracy: YELLOW -- The core opportunity premise (Orphan Designation, pipeline) is confirmed by company and industry sources, but specific catalysts like trial start dates and partnership models are less precisely dated or remain forward-looking statements.
Sources
PUBLIC
[Miramoon Pharma website] Halting Degeneration - MIRAMOON PHARMA | https://www.miramoonpharma.com/
[El Referente] Miramoon Pharma - El Referente | https://elreferente.es/startup/miramoon-pharma/?refrc=1
[AseBio, Nov 2025] Miramoon Pharma Breakthrough: Two Lead Candidates Show Promise | https://www.asebio.com/en/news-events/news/miramoon-pharma-breakthrough-two-lead-candidates-show-promise-prestigious
[economia3.com] A. Capilla, Miramoon Pharma: “No hay sueldo que recupere el tiempo perdido" | https://economia3.com/a-capilla-miramoon-pharma-no-hay-sueldo-que-recupere-el-tiempo-perdido/
[BStartup Banco Sabadell] BStartup10 lidera una ronda de inversión en Miramoon Pharma - BStartup Banco Sabadell | https://bstartup.bancsabadell.com/bstartup10-lidera-una-ronda-de-inversion-en-miramoon-pharma/
[Capital-Riesgo.es] BStartup10 leads an investment round in Miramoon Pharma | https://capital-riesgo.es/en/articles/bstartup10-leads-an-investment-round-in-miramoon-pharma/
[IOVS | ARVO Journals] Topical administration of MP-004 improves retinal function and structure in a mouse model of retinitis pigmentosa. | https://iovs.arvojournals.org/article.aspx?articleid=2789757
[bioRxiv, 2024] Topical administration of novel FKBP12 ligand MP-004 improves retinal function and structure in retinitis pigmentosa models | https://www.biorxiv.org/content/10.1101/2024.10.17.618826v1.full
[Biotech Spain] Miramoon Pharma Receives Orphan Drug Designation for MP-004 | AseBio | https://www.asebio.com/en/news-events/news/miramoon-pharma-receives-orphan-drug-designation-mp-004
[bioRxiv, 2025] Assessment of the pharmacological and safety profile of the small molecule MP-004 after topical eye drops administration | https://www.biorxiv.org/content/10.1101/2025.10.09.681374v1
[SPRI] Not available in provided snippets. Source omitted.
[AseBio] Miramoon Pharma Receives Orphan Drug Designation for MP-004 | AseBio | https://www.asebio.com/en/news-events/news/miramoon-pharma-receives-orphan-drug-designation-mp-004
[Grand View Research, 2023] Not available in provided snippets. Source omitted.
[Capital-Riesgo.es] Pinama Capital invests in biotechnology company Miramoon Pharma | https://capital-riesgo.es/en/articles/pinama-capital-invests-in-biotechnology-company-miramoon-pharma/
Articles about Miramoon Pharma
- Miramoon Pharma's Eye Drop Clears a Preclinical Path for Retinitis Pigmentosa — The Spanish biotech, backed by regional VCs, has secured orphan drug status for its lead asset and plans a 2026 clinical trial.